EUVIMEDAvasta EUVIMED
Open access

Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing

Babak J Orandi iD, Yiting Li iD, Timur Seckin iD, Sunjae Bae iD, Bonnie E Lonze iD, Christine J Ren-Fielding, Holly Lofton, Akash Gujral, Dorry L Segev iD, Mara McAdams-DeMarco iD

Clinical Transplantation · 2024

DOI: 10.1111/ctr.15414 ↗

At a glance

Journal article in Clinical Transplantation, 2024. Written by Babak J Orandi and 9 co-authors. Institution: Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA. Major MEDLINE topics: Kidney Failure, Chronic, Obesity, Kidney Transplantation, Body Mass Index. Cited 1 times so far (Crossref); 42 references. The full text is freely available in PubMed Central. Funded by: NIDDK NIH HHS, NIA NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstraktSubjectsBibliograafilised andmedCiteRelated studies

Abstract (original language)

Objectives

Obesogenic medications are a putative contributor to the obesity epidemic. While 20% of adults take ≥1 obesogenic medication, the proportion in the end‐stage kidney disease (ESKD) population—a group enriched for cardiometabolic complications—is unknown. Obesogenic medications may contribute to obesity and hamper weight loss efforts to achieve transplant listing.

Methods

Using 2017–2020 USRDS and Medicare claims, patients were identified as taking obesogenic medications if prescribed anticonvulsants, antidepressants, antidiabetics, anti‐inflammatories, antipsychotics, and/or antihypertensives known to cause weight gain for ≥30 days in their first hemodialysis year. Ordinal logistic and Cox regression with inverse probability of treatment weighting were used to quantify obesogenic medications’ association with body mass index (BMI) and listing, respectively.

Results

Among 271 401 hemodialysis initiates, 63.5% took ≥1 obesogenic medication. For those in underweight, normal weight, overweight, and class I, II, and III categories, 54.3%, 58.4%, 63.1%, 66.5%, 68.6%, and 68.8% took ≥1, respectively. Number of obesogenic medications was associated with increased BMI; use of one was associated with 13% increased odds of higher BMI (aOR [adjusted odds ratio] 1.14; 95%CI: 1.13–1.16; p < 0.001), use of three was associated with a 55% increase (aOR 1.55; 95%CI: 1.53–1.57; p < 0.001). Any use was associated with 6% lower odds of transplant listing (aHR [adjusted hazard ratio] 0.94; 95%CI: 0.92–0.96; p < 0.001). Within each BMI category, obesogenic medication use was associated with lower listing likelihood.

Conclusions

Obesogenic medication use is common in ESKD patients—particularly those with obesity—and is associated with lower listing likelihood. Whenever possible, non‐obesogenic alternatives should be chosen for ESKD patients attempting weight loss to achieve transplant listing.

Subjects

MeSH terms (MEDLINE)

Kidney Failure, ChronicObesityKidney TransplantationBody Mass IndexHumansMaleFemaleMiddle AgedFollow-Up StudiesAgedPrognosisRisk FactorsUnited StatesWaiting ListsAdultRetrospective StudiesGlomerular Filtration RateKidney Function Tests

Author keywords

USRDSdialysisend‐stage kidney diseaseobesity

Authors and institutions

  • Department of Surgery, New York University Grossman School of Medicine, New York, New York, USA.
  • Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
  • Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.

ORCID profiles: Babak J Orandi, Yiting Li, Timur Seckin, Sunjae Bae, Bonnie E Lonze, Dorry L Segev, Mara McAdams-DeMarco

Funding

  • NIDDK NIH HHS
  • NIA NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Orandi, B. J., Li, Y., Seckin, T., Bae, S., Lonze, B. E., Ren-Fielding, C. J., Lofton, H., Gujral, A., Segev, D. L., & McAdams-DeMarco, M. (2024). Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing. Clinical Transplantation. https://doi.org/10.1111/ctr.15414

Vancouver

Orandi BJ, Li Y, Seckin T, Bae S, Lonze BE, Ren-Fielding CJ, et al. Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing. Clinical Transplantation. 2024. doi:10.1111/ctr.15414

BibTeX
@article{Orandi2024,
  author = {Orandi, Babak J and Li, Yiting and Seckin, Timur and Bae, Sunjae and Lonze, Bonnie E and Ren-Fielding, Christine J and Lofton, Holly and Gujral, Akash and Segev, Dorry L and McAdams-DeMarco, Mara},
  title = {Obesogenic Medication Use in End‐Stage Kidney Disease and Association With Transplant Listing},
  journal = {Clinical Transplantation},
  year = {2024},
  doi = {10.1111/ctr.15414}
}
Start for free →